144 related articles for article (PubMed ID: 15302308)
1. Gonadotropin-releasing hormone agonist with or without raloxifene: effects on cognition, mood, and quality of life.
Palomba S; Orio F; Russo T; Falbo A; Amati A; Zullo F
Fertil Steril; 2004 Aug; 82(2):480-2. PubMed ID: 15302308
[No Abstract] [Full Text] [Related]
2. Tibolone reverses the cognitive effects caused by leuprolide acetate administration, improving mood and quality of life in patients with symptomatic uterine leiomyomas.
Palomba S; Orio F; Falbo A; Oppedisano R; Tolino A; Zullo F
Fertil Steril; 2008 Jul; 90(1):165-73. PubMed ID: 18001721
[TBL] [Abstract][Full Text] [Related]
3. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas.
Palomba S; Orio F; Russo T; Falbo A; Cascella T; Doldo P; Nappi C; Lombardi G; Mastrantonio P; Zullo F
Hum Reprod; 2004 Jun; 19(6):1308-14. PubMed ID: 15117890
[TBL] [Abstract][Full Text] [Related]
4. An evidence-based approach to hormonal therapies for premenopausal women with fibroids.
Lethaby AE; Vollenhoven BJ
Best Pract Res Clin Obstet Gynaecol; 2008 Apr; 22(2):307-31. PubMed ID: 17905660
[TBL] [Abstract][Full Text] [Related]
5. [A clinical control study on the treatment of uterine leiomyoma with gonadotrophin releasing hormone agonist or mifepristone].
Zeng C; Gu M; Huang H
Zhonghua Fu Chan Ke Za Zhi; 1998 Aug; 33(8):490-2. PubMed ID: 10806751
[TBL] [Abstract][Full Text] [Related]
6. Raloxifene administration in premenopausal women with uterine leiomyomas: a pilot study.
Palomba S; Orio F; Morelli M; Russo T; Pellicano M; Zupi E; Lombardi G; Nappi C; Panici PL; Zullo F
J Clin Endocrinol Metab; 2002 Aug; 87(8):3603-8. PubMed ID: 12161482
[TBL] [Abstract][Full Text] [Related]
7. Single or repeated gonadotropin-releasing hormone agonist treatment avoids hysterectomy in premenopausal women with large symptomatic fibroids with no effects on sexual function.
Perrone AM; Pozzati F; Di Marcoberardino B; Rossi M; Procaccini M; Pellegrini A; Santini D; De Iaco P
J Obstet Gynaecol Res; 2014 Jan; 40(1):117-24. PubMed ID: 24033631
[TBL] [Abstract][Full Text] [Related]
8. Elevated level of plasma vascular endothelial growth factor after gonadotropin-releasing hormone agonist treatment for leiomyomata.
Takeda T; Osuga K; Miyake A; Wakabayashi A; Morishige K; Kimura T
Gynecol Endocrinol; 2008 Dec; 24(12):724-6. PubMed ID: 19172544
[TBL] [Abstract][Full Text] [Related]
9. Antiproliferative and proapoptotic effects of raloxifene on uterine leiomyomas in postmenopausal women.
Palomba S; Orio F; Russo T; Falbo A; Tolino A; Lombardi G; Cimini V; Zullo F
Fertil Steril; 2005 Jul; 84(1):154-61. PubMed ID: 16009171
[TBL] [Abstract][Full Text] [Related]
10. Effects of gonadotropin-releasing hormone agonists on uterine leiomyomas.
Cramer SF
Arch Pathol Lab Med; 1998 Dec; 122(12):1045-6. PubMed ID: 9870847
[No Abstract] [Full Text] [Related]
11. Medical treatment of uterine fibroids.
Chavez NF; Stewart EA
Clin Obstet Gynecol; 2001 Jun; 44(2):372-84. PubMed ID: 11347559
[No Abstract] [Full Text] [Related]
12. GnRH agonist therapy before myomectomy or hysterectomy.
Gutmann JN; Corson SL
J Minim Invasive Gynecol; 2005; 12(6):529-37; quiz 528, 538-9. PubMed ID: 16337584
[No Abstract] [Full Text] [Related]
13. A systematic review of the psychosocial impact of fibroids before and after treatment.
Go VAA; Thomas MC; Singh B; Prenatt S; Sims H; Blanck JF; Segars JH
Am J Obstet Gynecol; 2020 Nov; 223(5):674-708.e8. PubMed ID: 32474012
[TBL] [Abstract][Full Text] [Related]
14. Does raloxifene inhibit the growth of uterine fibroids?
Palomba S; Zullo F; Orio F; Lombardi G
Fertil Steril; 2004 Jun; 81(6):1719-20; author reply 1720-1. PubMed ID: 15193512
[No Abstract] [Full Text] [Related]
15. Pathological evaluation of uterine leiomyomas treated with gonadotropin-releasing hormone agonist (GnRH-a) therapy: role of mast cells and a possible mechanism of GnRH-a resistance in leiomyomas.
Nakayama M; Mitsuhashi T; Shimizu Y; Ishihara O; Shimizu M
Pathol Int; 2008 May; 58(5):268-74. PubMed ID: 18429824
[TBL] [Abstract][Full Text] [Related]
16. The burden of uterine fibroids in five European countries.
Downes E; Sikirica V; Gilabert-Estelles J; Bolge SC; Dodd SL; Maroulis C; Subramanian D
Eur J Obstet Gynecol Reprod Biol; 2010 Sep; 152(1):96-102. PubMed ID: 20598796
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of leiomyomas with gonadoliberin agonists].
Puzigaca Z; Prelevic G; Markovic A
Srp Arh Celok Lek; 2001; 129(5-6):143-6. PubMed ID: 11797463
[No Abstract] [Full Text] [Related]
18. [GnRH analogues and myomas: which strategy?].
Poncelet C
Gynecol Obstet Fertil; 2005 Dec; 33(12):1018. PubMed ID: 16316770
[No Abstract] [Full Text] [Related]
19. [GnRH agonists and antagonists in the preoperative therapy of uterine fibroids: literature review].
De Falco M; Pollio F; Pontillo M; Ambrosino E; Busiello A; Carbone IF; Ciociola F; Di Nardo MA; Landi L; Di Lieto A
Minerva Ginecol; 2006 Dec; 58(6):553-60. PubMed ID: 17108883
[TBL] [Abstract][Full Text] [Related]
20. Prediction of the effects of gonadotropin-releasing hormone agonist therapy in uterine leiomyoma by T1 contrast-enhanced magnetic resonance imaging sequences.
Kadowaki M; Murakami T; Morita J; Terada Y; Yaegashi N; Okamura K
Fertil Steril; 2002 May; 77(5):1081-2. PubMed ID: 12009376
[No Abstract] [Full Text] [Related]
[Next] [New Search]
